Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease.

Franco-Maside A, Caamano J, Gomez MJ, Cacabelos R. 

Department of Digital Diagnosis,
Basic and Clinical Neurosciences Research Center,
La Coruna, Spain.
Exp Clin Pharmacol 1994 Oct;16(8):597-607

Abstract

CDP-choline participates in brain phospholipid metabolism and acts as an endogenous intermediate in a biosynthetic pathway incorporating free choline into phosphatidylcholine and choline plasmalogens in several tissues, including the central nervous system (CNS).  In patients with chronic cerebrovascular disorders, CDP-choline reduces the slow delta frequencies and increases alpha activity in spectral electroencephalogram analysis.  We have studied the effect of CDP-choline (cytidine-S-diphosphate-choline; 1000 mg/day x 30 days, p.o.) on brain electrical activity mapping and mental performance in 19 Alzheimer's disease (AD) patients (10 males/9 females; age: 66.21 +/- 1.48 years; Mini-Mental State Examination (MMSE): 26.55 +/- 1.22, Spanish version max. score 35). EEG was registered from 19 electrodes placed according to the 10-20 system and digitalized online. Artefact-free 2-s periods were visually selected, submitted to a frequency analysis and averaged across periods. CDP-choline significantly decreased spectral amplitude in the theta band in F4, F8, and T4 electrodes, and did not modify relative power parameters in any of the frequency bands (delta, theta, alpha, beta) as compared to basal recordings.  In patients with late-onset AD (LOAD; N = 6; age: 73.5 +/- 1.34 years; MMSE: 28.75 +/- 2.33), CDP-choline tended to increase relative alpha power in O1 and O2 electrodes. No changes were found in early-onset AD patients (EOAD; N = 13; age: 62.85 +/- 1.21 years; MMSE: 25.54 +/- 1.4).  We detected a significant improvement in mental performance after 1 month of treatment with CDP-choline in patients with early-onset AD in whom brain electrical activity data correlated with cognitive parameters.  It is likely that the bioelectrical changes induced by CDP-choline in AD are the result of its immunogenic and/or neurotrophic activity in the vicinity of the vascular microenvironment.

Galantamine | Vinpocetine | Idebenone | Pyritinol
 Picamilon | Modafinil | Deprenyl | Piracetam
Home | Order

Deprenyl Alzheimer's research                                                   www.deprenyl.info
       deprenyl   improves the performance of patients with Alzheimer's disease
       deprenyl   in the treatment of Alzheimer's disease
CDP Choline Alzheimer's research        !                                 www.cdpcholine.info
       CDP choline  may be useful in the treatment of Alzheimer's
       CDP choline  significant improvement after 1 month in early-onset Alzheimer's
       CDP choline  effects on cognition in patients with Alzheimer's
       CDP choline  significant improvement in Alzheimer's after 1 month  
       CDP choline  improved mental performance in Alzheimer's
Vinpocetine Alzheimer's research                  !                         www.vinpocetine.info
       vinpocetine  enhances oxygen release in vascular dementia  . 
       vinpocetine  article 
Piracetam Alzheimer's research                   !                            www.piracetam.info
       piracetam  improved alertness in Alzheimer's patients
       piracetam  improved cerebral glucose metabolism in Alzheimer's patients
       piracetam  use in Alzheimer's
       piracetam  therapy in Alzheimer's
       piracetam  a one year study of Alzheimer's patients 
       piracetam  article
Idebenone Alzheimer's research                      !                       www.idebenone.info
       Idebenone  versus Tacrine in Patients with Alzheimer's disease
       Idebenone  efficacy of idebenone in the treatment of Alzheimer's disease
       Idebenone  Nerve Growth Factor synthesis stimulators in Alzheimer's disease
       Idebenone  in the treatment of dementia of the Alzheimer type
       Idebenone  cognitive enhancement therapy for Alzheimer's disease
       Idebenone  study in the treatment of Alzheimer's disease
       Idebenone  two year study indicates idebenone slows Alzheimer's progression
       Idebenone  stimulates NGF synthesis in the treatment of Alzheimer's disease
       Idebenone  article
Pyritinol Alzheimer's research                          !                        www.pyritinol.info
       pyritinol  improved cognition in 100 dementia patients
       pyritinol  produced significant improvement in 40 dementia patients
       pyritinol  had therapeutic effect on 156 senile dementia patients
       pyritinol  improved cognitive performance in 26 dementia patients
       pyritinol  improved cerebral glucose metabolism in dementia
       pyritinol  article
 
.

Memantine Alzheimer's research                                              www.memantine.info

       Memantine  efficacy in patients with dementia
       Memantine  in senile dementia, Alzheimer type
       Memantine  and advanced dementia
       Memantine  for neuroprotection in dementia
       Memantine  in vascular dementia
       Memantine  in mild to moderate dementia
Galantamine Alzheimer's research                                            www.galantamine.cc
       galantamine  efficacy of galantamine in dementia and Alzheimer's disease
       galantamine  for Alzheimer's disease
       galantamine  novel approach to the treatment of Alzheimer disease
       galantamine  maintaining cognitive function in Alzheimer disease
       galantamine  maintaining functional abilities in Alzheimer disease
       galantamine  a new Alzheimer disease drug with a past life
       galantamine  treating vascular dementia with galantamine
       galantamine  rationale for switching from donepezil to galantamine
       galantamine  switching previous therapies for Alzheimer's disease to galantamine
       galantamine  its use in Alzheimer's
       galantamine  a new treatment for Alzheimer's
       galantamine  benefits to Alzheimer's patients
       galantamine  efficacy in mild to moderate Alzheimer's disease
       galantamine  effects on the course of Alzheimer's disease
       galantamine  a 5 month Alzheimer's study
       galantamine  effects in patients previously treated with donepezil
       galantamine  a six month Alzheimer's study
       galantamine  therapeutic effects beyond cognition in Alzheimer's disease
       galantamine  cognitive function in Alzheimer's disease
       galantamine  maintains cognitive function for at least 1 year
       galantamine  increase the density of brain nicotinic receptors
       galantamine  treatment for mild to moderate Alzheimer's disease.
       galantamine  may be effective as a cognition-enhancer in Alzheimer's disease
       galantamine  differs from other acetylcholine esterase inhibitors
       galantamine  safety and tolerability
       galantamine  dual mode of action for Alzheimer's disease
       galantamine  provides benefits for Alzheimer's for up to six months  .  
            article    Galantamine fights Alzheimer's
            article    Why galantamine is better than Aricept® and Exelon ®
            article    Galantamine can sharpen your mental edge
            article    Galantamine helps save memory
            article    Galantamine for combating mental decline
            article    Galantamine opens the channels of your memory
            article    Galantamine boosts memory
            article    Galantamine rescues brain cells
            article    Galantamine helps your memory
            article    Galantamine memory enhancement therapy
            article    Galantamine may help stave off dementia
            article    Galantamine enhances neurotransmission
            article    Galantamine increases acetylcholline
            article    Galantamine has benefits over Aricept®

 

Hit Counter

 
 
 

 

 

Hit Counter